STAT

FEBRUARY 8, 2024

On Thursday, at a press briefing at which they presented their 2023 earnings, AstraZeneca executives also played coy about the bargaining over the price of the company’s diabetes drug Farxiga.   “We are in active negotiation, and it will be a few rounds of discussions” with Medicare.

Drug Pricing 276

Drug Pricing Diabetes 276

The Pharmacist

AUGUST 9, 2023

Diabetes drug semaglutide, marketed as Wegovy, could also reduce risk of cardiovascular events by 20%, its manufacturer has claimed. Novo Nordisk has announced headline findings from its SELECT trial, although they have not yet been published in a peer-reviewed journal.

Diabetes 98

Diabetes 98

European Pharmaceutical Review

OCTOBER 18, 2023

TZIELD (teplizumab-mzwv) has demonstrated TZIELD’s potential to slow disease progression in newly diagnosed children and adolescents with Stage 3 type 1 diabetes. HbA1c reductions and the overall rates of clinically important hypoglycemic events were similar among both study groups. As the primary endpoint, 94.9

Diabetes 111

Diabetes 111

Express Pharma

NOVEMBER 7, 2023

The type 2 diabetes (T2D) landscape has historically been dominated by insulin receptor (IR) targeting drugs. This condition disrupts glucose metabolism, resulting in high blood glucose levels and a variety of effects thereafter, such as an increased risk of stroke and diabetic neuropathy. IR’s role in T2D is well-defined.

Diabetes 111

Diabetes 111

European Pharmaceutical Review

JUNE 27, 2023

Lonza and Vertex Pharmaceuticals Incorporated have agreed to collaborate to support the manufacture of Vertex’s Type 1 diabetes cell therapy portfolio. Participants with greater than 90 days of follow-up had elimination of severe hypoglycaemic events in the evaluation period.

Diabetes 98

Diabetes Immunization Immunity 98

PharmExec

APRIL 1, 2025

In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 diabetes and cardiovascular disease and/or chronic kidney disease.

Diabetes 52

Diabetes 52

STAT

JANUARY 4, 2024

Food and Drug Administration is evaluating reports of side effects such as hair loss and suicidal thoughts in people taking medications known as GLP-1 receptor agonists, which are approved to treat diabetes or weight loss , CNN reports. These include Ozempic, Rybelsus, Wegovy, Saxenda, Victoza, Mounjaro, and Zepbound.

Biosimilars 285

Biosimilars Diabetes 285

STAT

JULY 26, 2024

The European Medicines Agency backed the use of Novo Nordisk’s Wegovy to lower major heart risks and strokes in overweight or obese adults without diabetes , Reuters notes. Food and Drug Administration approved the drug for prevention of cardiovascular events in people with obesity earlier this year.

Labelling 266

Labelling Diabetes 266

Pharmaceutical Technology

NOVEMBER 18, 2022

The US Food and Drug Administration (FDA) has approved Provention Bio’s biologics licence application (BLA) for Tzield (teplizumab-mzwv) to treat type 1 diabetes (T1D) patients. The post US FDA approves Provention Bio’s Tzield to delay diabetes appeared first on Pharmaceutical Technology.

Diabetes 98

Diabetes 98

PharmD Live

NOVEMBER 12, 2024

In recognition of American Diabetes Month , the growing need for effective, accessible and patient-centered diabetes care is emphasized. Approximately 38 million Americans live with diabetes, a condition requiring multiple medications, lifestyle adjustments and frequent monitoring to prevent serious complications. As the U.S.

Diabetes 52

Diabetes Communication 52

Express Pharma

MAY 11, 2023

Stempeutics Research recently completed enrollment in the Phase 3 clinical trial evaluating a single peri-ulcer injection of its proprietary allogeneic mesenchymal stromal cell product candidate Stempeucel-DFU in patients with non-healing diabetic foot ulcer. Phase 3 trial has been approved by DCGI.

Diabetes 94

Diabetes 94

STAT

SEPTEMBER 13, 2024

We plan to catch up on sundry tasks, promenade with the official mascots and escort Mrs. Pharmalot to an event or two. This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda has possibilities. And what about you? This remains a fine time to enjoy the great outdoors. Well, whatever you do, have a grand time.

Medical Records 243

Medical Records Labelling Diabetes Drug Pricing 243

pharmaphorum

MARCH 5, 2024

Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabetes and chronic kidney disease (CKD) in the FLOW trial.

Diabetes 110

Diabetes 110

Pharmafile

JUNE 24, 2024

Vertex Pharmaceuticals has announced new data from its phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy in patients with type 1 diabetes (T1D) with impaired hypoglycaemic awareness and severe hypoglycaemic events (SHEs).

Diabetes 52

Diabetes 52

Pharmacy Times

NOVEMBER 2, 2022

The drug is a selective, nonsteroidal mineralocorticoid receptor antagonist found to also protect against COVID-19 and pneumonia-related adverse events in patients with diabetes.

Diabetes 52

Diabetes 52

Express Pharma

MAY 6, 2024

The new nano carrier could help people with diabetes avoid side-effects linked to insulin injections such as hypoglycemia, inform the researchers Research led by the University of Sydney and Sydney Local Health District has developed a system using nanotechnology that could allow people with diabetes to take oral insulin in the future.

Diabetes 103

Diabetes 103

Drug Channels

MAY 16, 2024

At the recent Publicis Health Media HealthFront event, Preeti hosted a dialogue on the main stage with Dr. Minisha Sood. They discussed new GoodRx research and had a candid discussion about their daily challenges in caring for patients—especially those living with diabetes and obesity.

Diabetes 52

Diabetes 52

Express Pharma

JULY 28, 2024

Food and Drug Administration recently warned patients and doctors about dosing errors associated with compounded versions of Novo Nordisk’s weight-loss and diabetes drugs. Overdoses with these drugs could cause adverse effects including severe nausea, vomiting and low blood sugar levels,” it added.

Compounding 103

Compounding Diabetes 103

Pharmacy Times

JUNE 23, 2024

Jennifer Goldman discusses the importance of collaborative care between providers like endocrinologists, cardiologists, primary care physicians, and pharmacists to manage diabetes and prevent cardiovascular events.

Diabetes 42

Diabetes 42

Express Pharma

JUNE 28, 2023

The data was highlighted in poster presentations at the American Diabetes Association’s (ADA) 83rd Scientific Sessions held from June 23-26, 2023, in San Diego, CA. The data was highlighted in poster presentations at the American Diabetes Association’s (ADA) 83rd Scientific Sessions held from June 23-26, 2023, in San Diego, CA.

Diabetes 98

Diabetes 98

STAT

OCTOBER 25, 2024

… A turbulent series of events surrounding the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around how the U.S. Earlier this month, the FDA declared an end to the shortage of Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, after almost two years.

Compounding 187

Compounding Compounding Pharmacies Diabetes Drug Development 187

LifeProNow

MARCH 7, 2024

The Dexcom Stelo Glucose Biosensor System is an integrated CGM (iCGM) intended for anyone 18 years and older who does not use insulin, such as individuals with diabetes treating their condition with oral medications, or those without diabetes who want to better understand how diet and exercise may impact blood sugar levels.

Diabetes 130

Diabetes 130

pharmaphorum

NOVEMBER 2, 2022

One of the highlights of Eli Lilly’s third-quarter results was the rapid uptake of new type 2 diabetes therapy Mounjaro, which added more than $97 million in US sales alone in what has been described as “viral” take-up by the drugmaker.

Diabetes 105

Diabetes 105

Express Pharma

MARCH 2, 2025

As in earlier years, week-long events have been planned at various locations across the country from March 1 to 7, 2025. At the initiative of Prime Minister Narendra Modi, March 7 is celebrated every year as Jan Aushadhi Diwas to enhance awareness about the scheme and promote generic medicines.

Generic Medicine 76

Generic Medicine Diabetes 76

pharmaphorum

MAY 21, 2021

Eli Lilly has scored five out of five with its phase 3 trials of type 2 diabetes candidate tirzepatide, setting up regulatory filings for a drug that the drugmaker thinks could be the lynchpin of its franchise in the coming years. . Treatment with Lilly’s drug also resulted in a 11.7

Diabetes 52

Diabetes 52

pharmaphorum

APRIL 29, 2022

For many patients with type 2 diabetes, having to inject basal insulin every day is a burdensome fact of life, but Novo Nordisk is trying to change that. events for the once-daily drug. In absolute terms, there were 0.73 cases of hypoglycaemia per year with insulin icodec, versus 0.27

Diabetes 98

Diabetes 98

Pharmaceutical Technology

OCTOBER 22, 2024

The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with type 2 diabetes.

Labelling 64

Labelling Diabetes 64

Pharmaceutical Technology

OCTOBER 4, 2022

The type 2 diabetes (T2D) space recently witnessed a new approval: on 15 September, the European Commission (EC) authorised Eli Lilly’s Mounjaro (tirzepatide) for T2D patients. With respect to its safety profile, adverse events ranged from mild to moderate among subjects, and treatment discontinuation due to adverse events was 6.2%

Diabetes 105

Diabetes 105

Pharmacy Times

MARCH 14, 2025

The new data emphasize the fundamental differences in management and associated complications with each form of diabetes.

Diabetes 32

Diabetes 32

pharmaphorum

MARCH 3, 2022

The results of the EMPULSE trial showed that adults hospitalised for acute heart failure were 36% more likely to see an improvement on clinical measures – including all-cause mortality, frequency of heart failure events, time to first heart failure event, and symptoms – in the first 90 days after treatment started compared to placebo.

Labelling 98

Labelling Diabetes Hospitals 98

Pharma Marketing Network

NOVEMBER 24, 2024

Optimize your website to be mobile-friendly and create value-driven content around trending topics like “best treatment options for diabetes” to drive traffic. For instance, a diabetes educator discussing the benefits of Ozempic can create authenticity and trust in your brand. Tailor messages for each platform.

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies 52

Digital Pharmacist

FEBRUARY 29, 2024

Originally announced with public service announcements, news releases, and bumper stickers which promoted special nutrition events hosted in schools, health care facilities, and community centers, the campaign caught national attention with districts and state associations being prompted to host their own events.

Health and Personal Care Stores 111

Health and Personal Care Stores Diabetes 111

Pharmaceutical Technology

APRIL 20, 2023

Zucara Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug application for ZT-01 to prevent night-time (nocturnal) hypoglycaemia in type 1 diabetes (T1D) patients. The rate of nocturnal hypoglycaemic events is the primary endpoint of the trial.

Diabetes 52

Diabetes 52

pharmaphorum

AUGUST 24, 2022

ESRD patients tend to have underlying conditions like diabetes, high blood pressure, atrial fibrillation, and cardiovascular disease that increase their risk of blood clots, and systemic anticoagulants are routinely used as a preventative measure. . “Today there is no anticoagulation standard of care for such patients,” he added.

Diabetes 115

Diabetes 115

Pharmaceutical Technology

NOVEMBER 30, 2022

The drug was approved to treat type 2 diabetes mellitus in May. High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. Anti-obesity therapeutic landscape.

Insurance Coverage and Processing 105

Insurance Coverage and Processing Diabetes Labelling Communication 105

The Thyroid Pharmacist

SEPTEMBER 2, 2022

A review paper published in 2010 that discussed the relationship between thyroid dysfunction and metabolic disorders, highlighted the fact that patients with diabetes were up to three times more likely to develop a thyroid disorder. (7). Hypoglycemia is an early risk factor for developing diabetes. Type 2 Diabetes.

Diabetes 98

Diabetes Health and Personal Care Stores Immunity Immunization 98

Pharmaceutical Technology

JUNE 8, 2023

This patient later encountered a respiratory-related adverse event within 21 days of the nine-month assessment, per the release. Both the aerosol delivery and the therapy itself were well tolerated, with no related adverse events. The third participant’s score improved by six points after six months.

Diabetes 98

Diabetes 98